These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 9151914

  • 1. Factors associated with survival exceeding 5 years after transcatheter arterial embolization for hepatocellular carcinoma.
    Yoshioka H, Sato M, Sonomura T, Terada M, Kishi K, Yoshikawa A.
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-29-S6-37. PubMed ID: 9151914
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors in resected hepatocellular carcinomas and therapeutic value of transcatheter arterial embolization for recurrences.
    Kimura H, Yabushita K, Konishi K, Maeda K, Kuroda Y, Tsuji M, Demachi H, Miwa A.
    Int Surg; 1998 Apr; 83(2):146-9. PubMed ID: 9851333
    [Abstract] [Full Text] [Related]

  • 3. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
    Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, Hayashi S, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, Sakata Y, Shimamura Y, Jinno K, Takahashi A, Takayasu K, Tamura K, Nagasue N, Nakanishi Y, Makino M, Masuzawa M, Yumoto Y, Mori T, Oda T.
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-38-S6-45. PubMed ID: 9151915
    [Abstract] [Full Text] [Related]

  • 4. [A comparison of patients with hepatocellular carcinoma between a short-term (less than 6 months) survival group and a long-term (over 24 months) survival group after treatment with transcatheter arterial chemoembolization].
    Kang IK, Kim SW, Hahn SH, Cho SC, Gham CW, Lee DH.
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):189-200. PubMed ID: 12499805
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcomes of transcatheter arterial chemoembolization with autologous blood clot for unresectable hepatocellular carcinoma.
    Gunji T, Kawauchi N, Akahane M, Watanabe K, Kanamori H, Ohnishi S.
    Int J Oncol; 2002 Aug; 21(2):427-32. PubMed ID: 12118341
    [Abstract] [Full Text] [Related]

  • 6. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY.
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Usefulness of tumor pressure as a prognostic factor in cases of hepatocellular carcinoma where the diameter of the tumor is 3 cm or less.
    Ueki T, Sakaguchi S, Miyajima Y, Hatono N, Tohara K, Nakabayashi S, Yao T, Kokawa H, Hirano M, Okumura M.
    Cancer; 2002 Aug 01; 95(3):596-604. PubMed ID: 12209753
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combination therapy with transcatheter arterial embolization and percutaneous ethanol injection for advanced hepatocellular carcinoma.
    Koda M, Okamoto K, Miyoshi Y, Kato S, Murawaki Y, Horie Y, Suou T, Kawasaki H.
    Hepatogastroenterology; 1994 Feb 01; 41(1):25-9. PubMed ID: 8175109
    [Abstract] [Full Text] [Related]

  • 11. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B, Yu J, Wang L, Li C, Zhou T, Zhai L, Xing L.
    Am J Clin Oncol; 2003 Aug 01; 26(4):e92-9. PubMed ID: 12902905
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study.
    Huang YH, Chen CH, Chang TT, Chen SC, Wang SY, Lee PC, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Chau GY, Chiang JH, Lui WY, Lee SD, Wu JC.
    Liver Int; 2004 Oct 01; 24(5):419-24. PubMed ID: 15482337
    [Abstract] [Full Text] [Related]

  • 17. Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization.
    Yamashita F, Tanaka M, Satomura S, Tanikawa K.
    Eur J Gastroenterol Hepatol; 1995 Jul 01; 7(7):627-33. PubMed ID: 8590157
    [Abstract] [Full Text] [Related]

  • 18. [Stage III, IV hepatocellular carcinoma patients surviving more than five years after transcatheter chemoembolization].
    Nakamura H, Mitani T, Murakami T, Hashimoto T, Nakanishi K, Maeshima S, Tsuda K, Tomoda K, Hori S, Kozuka T.
    Gan To Kagaku Ryoho; 1992 Aug 01; 19(10 Suppl):1756-8. PubMed ID: 1326925
    [Abstract] [Full Text] [Related]

  • 19. [The clinical course of nodular type hepatocellular carcinomas after transcatheter arterial embolization (TAE) therapy].
    Suyama Y, Kitagawa Y, Horishi M, Shizumi Y, Yashige H, Fujii H, Miyoshi M.
    Gan No Rinsho; 1989 Aug 01; 35(9):983-9. PubMed ID: 2475651
    [Abstract] [Full Text] [Related]

  • 20. Indication of chemoembolization therapy without gelatin sponge for hepatocellular carcinoma.
    Suzuki M, Suzuki H, Yamamoto T, Mamada Y, Mizuno H, Tominaga T, Suga M, Suemori S, Kato Y, Sato A, Yamanouchi E, Sakuyama K, Maeyama S, Shinagawa T, Okabe K.
    Semin Oncol; 1997 Apr 01; 24(2 Suppl 6):S6-110-S6-115. PubMed ID: 9151925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.